Brief: Prelude Therapeutics Posts Q1 Loss Per Share $0.47
11/05/2021 12:53
May 11 (Reuters) - Prelude Therapeutics Inc PRLD.O :
* Q1 LOSS PER SHARE $0.47
* Q1 EARNINGS PER SHARE ESTIMATE $-0.42 -- REFINITIV IBES
DATA
* INITIAL CLINICAL DATA READOUTS FOR LEAD ORAL PRMT5
INHIBITORS
PRT543 AND PRT811 EXPECTED IN H2 2021
* PRELUDE THERAPEUTICS - BELIEVES CURRENT CASH & CASH
EQUIVALENTS
WILL BE SUFFICIENT TO FUND OPERATING EXPENSES & CAPEX
REQUIREMENTS INTO 2023
Source text for Eikon: ID:nGNXcLKK3
Further company coverage: PRLD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Prelude Therapeutics Incorporated
See all newsBrief: Prelude Announces Clinical Trial Collaboration And Supply Agreement With Lilly To Evaluate KAT6A Selective Degrader PRT13722 In Combination With Verzenio® And Inluriyo® In Patients With HR+/HER2- Breast Cancer
U.S. RESEARCH ROUNDUP-Celcuity, Fluence Energy, Salesforce
Prelude Therapeutics Incorporated reports results for the quarter ended June 30 - Earnings Summary
Prelude Therapeutics Q2 revenue beats analyst expectations, net loss narrows
Prelude Therapeutics Incorporated expected to post a loss of 20 cents a share - Earnings Preview